ELOX Stock Chart & Stats
$0.17
$0.00(0.00%)
At close: 4:00 PM EST
$0.17
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.23 - $17.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)32.00
Market Cap
$504.09K
Enterprise Value$13.98
Total Cash (Recent Filing)$6.36M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-2080.33
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,938
10 Day Avg. Volume32
30 Day Avg. Volume32
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Eloxx Pharmaceuticals News
ELOX FAQ
What was Eloxx Pharmaceuticals’s price range in the past 12 months?
Eloxx Pharmaceuticals lowest stock price was $0.23 and its highest was $17.50 in the past 12 months.
What is Eloxx Pharmaceuticals’s market cap?
Eloxx Pharmaceuticals’s market cap is $504.09K.
When is Eloxx Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Eloxx Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Eloxx Pharmaceuticals overvalued?
According to Wall Street analysts Eloxx Pharmaceuticals’s price is currently Overvalued.
Does Eloxx Pharmaceuticals pay dividends?
Eloxx Pharmaceuticals does not currently pay dividends.
What is Eloxx Pharmaceuticals’s EPS estimate?
Eloxx Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eloxx Pharmaceuticals have?
Eloxx Pharmaceuticals has 41,938 shares outstanding.
What happened to Eloxx Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eloxx Pharmaceuticals?
Currently, no hedge funds are holding shares in ELOX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eloxx Pharmaceuticals
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Technical Analysis
AIM ImmunoTech
―
Biodexa Pharmaceuticals
―
―
Dermata Therapeutics
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
51.60% Insiders
<0.01% Other Institutional Investors
48.40% Public Companies and
Individual Investors